Сorrection of increased muscular tone using baclofen in diseases and injuries of the nervous system


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Baclofen is a derivative of chlorophenylbutyric acid, and can be considered as a derivative of GABA, which determines the specificity of its pharmacological effects. Therefore, the features of the mechanism of action of the drug can not be considered as definitively clarified [1]. The baclofen-induced miorelaxation is based primarily on the effect at the spinal level and is associated with the suppression of monosynaptic and polysynaptic reflexes, as well as a decrease in the activity of gamma motoneurons. Further evaluation of its mechanisms of action and clinical effectiveness, and the introduction of new dosage forms will help expand the application of this drug in neurological practice.

Full Text

Restricted Access

About the authors

Andrey P. Rachîn

Russian Scientific Center of Medical Rehabilitation and Balneology

Email: andrey_ratchin@mail.ru
MD, professor, head of the Department of neurology

Svetlana N. Vygovskaya

Russian Scientific Center of Medical Rehabilitation and Balneology

PhD, senior researcher, Department of neurology

Margarita B. Nuvakhova

Russian Scientific Center of Medical Rehabilitation and Balneology

PhD, senior researcher, Department of neurology

Aleksey A. Voropaev

Russian Scientific Center of Medical Rehabilitation and Balneology

PhD, senior researcher, Department of neurology

Anastasiya A. Averchenkova

Russian Scientific Center of Medical Rehabilitation and Balneology

PhD, Department of neurology

References

  1. Белова А.Н. Спастический паралич. Нейрореабилитация: Руководство для врачей. Глава 4. Принципы восстановительного лечения при основных неврологических синдромах. Москва, 2000. [Belova A.N. Spastic paralysis. Neurorehabilitation: Guidance for doctors. Chapter 4. Principles of restorative treatment of the major neurological syndromes. Moscow, 2000 (in Russ.)]
  2. Чуканова Е.И. Миорелаксация - ведущее звено в терапии болезненного мышечного спазма. Медицинская газета «Здоровье Украины». 2004;91. [Chukanova Ye.I. Muscle relaxation - a key factor in the treatment of painful muscle spasm. Medical newspaper «Health of Ukraine». 2004;91 (in Russ.)]
  3. Гусев Е.И., Гехт А.Б. Спастичность. РМЖ. 1999;12:567. [Gusev Ye.I., Gekht A.B. Spasticity. Russian medical journal. 1999;12:567 (in Russ.)]
  4. Бурчинский С.Г. Принципы и средства фармакологической коррекции болевых спастических синдромов в неврологии. Институт геронтологии АМН Украины, Киев. Клинический обзор. [Burchinsky S.G. Principles and means of pharmacological correction of spastic pain syndromes in neurology. Institute of gerontology of AMS of Ukraine, Kiev. Clinical review (in Ukr.)]
  5. Guglielmino A., Sorbello M., Fazzio S., Zingale S.F., Bucolo G.E., Pittalà G., Castiglione A., Patti F., Mangiameli S. Continuous intrathecal baclofen administration by a fully implantable electronic pump for severe spasticity treatment: our experience. Minerva Anestesiol. 2006;72(10):807-20.
  6. Shakespeare D.T., Boggild M., Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev. 2003;(4):CD001332.
  7. Brar S.P., Smith M.B., Nelson L.M., Franklin G.M., Cobble N.D. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Archives of Physical Medicine & Rehabilitation. 1991;72(3):186-9.
  8. Pellkofer M., Paulig M. Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities. Medizinische Klinik. 1989;84(1):5-8.
  9. Taricco M., Adone R., Pagliacci C., Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst. Rev. 2000;(2):CD001131.
  10. Penn R., Savoy S., Corcos D., Latash M., Gottlieb G., Parke B., Kroin J.S. Intrathecal baclofen for severe spinal spasticity. N. Engl. J. Med. 1989;320(23):1517-21.
  11. Hugenholts H., Nelson R.F., Dehoux E., Bickerton R. Intrathecal baclofen for intractable spinal spasticity-a double blind crossover study in eight patients. Can. J. Neurol. Sci. 1992;19:188-95.
  12. Burke D., Gillies J., Lance J. An objective assessment of a gamma aminobutyric acid derivative in the control of spasticity. Proceedings of the Australian Association of Neurology. 1971;8:131-4.
  13. Taira T., Ochiai T., Goto S., Hori T. Fifteen year experience of intrathecal baclofen treatment in Japan. Acta. Neurochir. Suppl. 2006;99:61-3.
  14. Shelenberger M., Groves L., Novack G.D. A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state. Drug Metab. Dispos. 1999;27(2):201-4.
  15. Albright A.L., Ferson S.S. Intrathecal baclofen therapy in children. Neurosurg. Focus. 2006;15:21(2).
  16. Heinzerling K.G., Shoptaw S., Peck J.A., Yang X., Liu J., Roll J., Ling W. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85(3):177-84. 17.
  17. Flannery B.A., Garbutt J.C., Cody M.W., Renn W., Grace K., Osborne M., Crosby K., Morreale M., Trivette A. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin. Exp. Res. 2004;28(10):1517-23.
  18. Shoptaw S., Yang X., Rotheram-Fuller E.J., Hsieh Y.C., Kintaudi P.C., Chauvastra V.C., Lind W. Randomized placebocontrolled trial of baclofen for cocsine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J. Clin. Psychiatry. 2003;64(12):1440-8.
  19. Reis G.M., Duarte I.D. Baclofen, an agonist at peripheral GABAB receptors, induces antinociception via activation of TEAsensitive potassium channels. Br. J. Pharmacol. 2006;149(6):733-9.
  20. Potes C.S., Neto F.L., Castro-Lopes J.M. Administration of baclofen, a gamma-aminobutyric acid type B agonist in the thalamic ventrobasal complex, attenuates allodynia in monoarthritic rats subjected to the ankle-bend test. J. Neurosci. Res. 2006;83(3):515-23.
  21. Рачин А.П. Доказательная фармакоаналитика терапии остеоартроза. Фарматека. 2007;19:81-6. [Rachin A.P. Evidence-based of farmacocanalytics of therapy of osteoarthritis. Pharmateca. 2007;19:81-6 (in Russ.)]
  22. Юдельсон Я.Б., Нечаев В.И. Морфофункциональные аспекты вертеброневрологии. Неврологический журнал. 2000;6:33. [Yudelson Ya.B., Nechaev V.I. Morpho-functional aspects of neurology. Neurological journal. 2000;6:33 (in Russ.)]
  23. Рачин А.П., Юдельсон Я.Б. Хроническая ежедневная головная боль у детей. Журнал неврологии и психиатрии им. C.C. Корсакова. 2005;1:83-5. [Rachin A.P., Yudelson Ya.B. Chronic daily headache in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2005;1:83-5 (in Russ.)]
  24. Юдельсон Я.Б., Рачин А.П. Особенности головной боли напряжения у детей и подростков. Вопросы современной педиатрии. 2003;5:51. [Yudelson Ya.B., Rachin A.P. Features of tension-type headache in children and adolescents. Issues of Modern Pediatrics. 2003;5:51 (in Russ.)]
  25. Рачин А.П., Юдельсон Я.Б., Сергеев А.В. Функциональные особенности мозга (по данным динамики потенциала Р300) в процессе хронизации ГБН. Патогенез. 2005;1:4-8. [Rachin A.P., Yudelson Ya.B., Sergeev A.V. Functional features of the brain (according to the dynamics of P300 potential) in the process of chronic TTH. Pathogenesis. 2005;1:48 (in Russ.)]
  26. Рачин А.П., Якунин К.А., Демешко А.В. Миофасциальный болевой синдром. Москва, 2009. [Rachin A.P., Yakunin K.A., Demeshko A.V. Myofascial pain syndrome. Moscow, 2009 (in Russ.)]
  27. He L., Wu B., Zhou M. Non-antiepileptic drugs for trigeminal neuralgia. Evid. Based Dent. 2006;7(4):107.
  28. Fromm G.H., Terrence C.F., Chattha A.S. Baclofen in the treatment of trigeminal neuralgia: double-blind study and longterm follow-up. Annals of Neurology. 1984;15(3):240-4.
  29. Parekh S., Shah K., Kotdawalla H., Gandhi I. Baclofen in carbamazepine resistant trigeminal neuralgia - A double blind clinical trial. Cephalalgia. 1989;9 (Suppl. 10):392-3.
  30. Рачин А.П. Десять доказательств успешного применения флупиртина (катадолона) при болях в нижней части спины. Лечение нервных болезней. 2007;21:35-9. [Rachin A.P. Ten evidences of the successful application of flupirtine (katadolon) for pain in the lower back. Treatment of nervous diseases. 2007;21:35-9 (in Russ.)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies